3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione | 63649-29-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione
• CAS: 63649-29-6
• 化学式: C₆H₇NO₃
• mdl: MFCD19217849
• 分子量: 141.126
• InChiKey: FCFIXIAXNVTUTF-UHFFFAOYSA-N

物化性质

• 沸点：
  254.4±50.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione 在 ammonium hydroxide 作用下， 生成 bis(3-pentyloctyl) 8,8’-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)azanediyl)dioctanoate
  参考文献：
  名称：

  LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS AND USES THEREOF

  摘要：

  This disclosure relates to ionizable amino lipid-based lipid nanoparticles for delivery of mRNA encoding propionyl-CoA carboxylase alpha (PCCA) and propionyl-CoA carboxylase beta (PCCB). Lipid nanoparticle/mRNA therapies of the invention increase and/or restore deficient levels of PCCA and/or PCCB expression and/or activity in subjects and are useful for the treatment of propionic academia.

  公开号：

  US20240216288A1
• 作为产物：
  描述：

  3,4-二甲氧基-3-环丁烯-1,2-二酮 在 甲胺 作用下， 以 乙醇 为溶剂， 生成 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione
  参考文献：
  名称：

  2-(2-Pyridylaminoalkylamino)-4-pyrimidones

  摘要：

  吡啶衍生物被披露，可用作组胺H.sub.1-拮抗剂。

  公开号：

  US04532246A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS D'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2018170306A1

  公开（公告）日：2018-09-20

  The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及新型脂质和相关组合物。纳米粒子组合物包括一种新型脂质以及额外的脂质，如磷脂、结构脂质和PEG脂质。纳米粒子组合物还包括治疗和/或预防措施，如RNA，在将治疗和/或预防措施传递给哺乳动物细胞或器官方面非常有用，例如，调节多肽、蛋白质或基因表达。
• 脂质化合物及其组合物
  申请人：广州市锐博生物科技有限公司

  公开号：CN113185421B

  公开（公告）日：2022-01-25

  本发明涉及一种脂质化合物及其组合物，包含其的脂质纳米颗粒，及其制备方法和在药物递送中的用途。
• NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20150087675A1

  公开（公告）日：2015-03-26

  Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

  揭示了符合通用公式（I）的二取代的3,4-二氨基-3-环丁烯-1,2-二酮化合物。还揭示了包括这些化合物的药物组合物以及使用这些化合物和组合物治疗趋化因子介导的疾病的方法。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• [EN] PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF<br/>[FR] DÉRIVÉS D'AMINE D'IMIDAZOQUINOLINE DE PHOSPHORE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS THÉRAPEUTIQUES CORRESPONDANTS
  申请人：YU NINGHUI

  公开号：WO2020163118A1

  公开（公告）日：2020-08-13

  The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLRS, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency.

  该发明提供了新型磷酸嘌呤喹啉胺衍生物，具有对Toll样受体（TLRs）的激动活性，特别是对TLR7和/或TLR8的激动活性，以及其药物组合物，以及治疗、减少或预防由TLR7和/或TLRs介导或相关的某些疾病或症状的方法，例如癌症、移植排斥、自身免疫、炎症过敏、哮喘、感染、败血症和免疫缺陷。